Feed CORT
CO

Corcept Therapeutics

CORT · NASDAQ

$114.86 +1.69% (+$1.91)
1M -6.06%
Market Cap $12.4B
P/E Ratio 226.30x
Div. Yield -
ROE 8.37%

Bulios Fair Price

$105.29

8.3% downside

Trenutna cena

$114.86

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica CORT trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Moderate
6/9
Valuation
0 /100
Expensive
P/E 226.30x
P/B 17.60x
EV/EBITDA 427.98x
Growth
60 /100
Stable
EPS growth 1.95%
Book val. growth 8.88%
Rev. growth 23.74%
Profitability
54 /100
Moderate
Gross margin 98.30%
FCF margin 12.87%
Net margin 6.61%
Quality
34 /100
Average
ROIC 2.03%
Asset turnover 0.93x
ROE 8.37%
Debt
100 /100
Low
Debt/Equity 0.01x
Net debt/EBITDA -3.53x
Current ratio 2.86x
Stability
72 /100
Stable
Beta 0.45x
Profitable years 6
Rev. volatility 14.06%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o CORT
Online

O podjetju

Corcept Therapeutics Incorporated (CORT) is an American biotechnology company specializing in research, development, and commercialization of drugs for the treatment of endocrine and psychiatric disorders. With activities in biotechnology and pharmacology, Corcept Therapeutics is a key player in the world of innovative treatment approaches. Their research focuses on discovering new treatment methods and therapies for patients with endocrine and psychiatric disorders, including Cushing's syndrome. The company aims to provide modern treatment solutions and improve the quality of life for patients. Corcept Therapeutics is characterized by expertise in pharmacology and endocrine medicine. Corcept Therapeutics Incorporated (CORT) shares could be suitable for investors looking for an investment opportunity in the biotechnology and pharmaceutical sector with a company that specializes in innovative treatment approaches and therapies for patients with endocrine and psychiatric disorders.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Medical - Pharmaceuticals

CEO

Joseph K. Belanoff

Employees

730

Headquarters

Redwood City

Prihajajoči dogodki

04 NOV.

Earnings

Upcoming earnings report

47d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.